{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:48:53Z","timestamp":1781761733968,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009447","name":"Leukemia and Lymphoma Society of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009447","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Princess Margaret Cancer Centre Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00262-023-03442-2","type":"journal-article","created":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T16:01:57Z","timestamp":1681574517000},"page":"2597-2612","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Engineered murine IL-21-secreting leukemia cells induce granzyme B+ T cells and CD4+CD44+CD62L\u2212 effector memory cells while suppressing regulatory T cells, leading to long-term survival"],"prefix":"10.1007","volume":"72","author":[{"given":"Alexandra","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Colpitts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Zych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Paige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,15]]},"reference":[{"issue":"4","key":"3442_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1053\/j.seminoncol.2015.05.015","volume":"42","author":"T Floros","year":"2015","unstructured":"Floros T, Tarhini AA (2015) Anticancer cytokines: biology and clinical effects of interferon-alpha2, interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol 42(4):539\u2013548","journal-title":"Semin Oncol"},{"issue":"4","key":"3442_CR2","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.3390\/cancers3043856","volume":"3","author":"S Lee","year":"2011","unstructured":"Lee S, Margolin K (2011) Cytokines in cancer immunotherapy. Cancers (Basel) 3(4):3856\u20133893","journal-title":"Cancers (Basel)"},{"issue":"8B","key":"3442_CR3","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1111\/j.1582-4934.2008.00412.x","volume":"13","author":"A Labbe","year":"2009","unstructured":"Labbe A et al (2009) IL-12 immunotherapy of murine leukaemia: comparison of systemic versus gene modified cell therapy. J Cell Mol Med 13(8B):1962\u20131976","journal-title":"J Cell Mol Med"},{"issue":"11","key":"3442_CR4","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1158\/2326-6066.CIR-13-0208","volume":"2","author":"ME Nelles","year":"2014","unstructured":"Nelles ME et al (2014) Murine splenic CD4(+) T cells, induced by innate immune cell interactions and secreted factors, develop antileukemia cytotoxicity. Cancer Immunol Res 2(11):1113\u20131124","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"3442_CR5","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/jcmm.12121","volume":"17","author":"LZ Wei","year":"2013","unstructured":"Wei LZ et al (2013) Localized interleukin-12 delivery for immunotherapy of solid tumours. J Cell Mol Med 17(11):1465\u20131474","journal-title":"J Cell Mol Med"},{"issue":"1","key":"3442_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s40425-019-0777-8","volume":"7","author":"A Berger","year":"2019","unstructured":"Berger A et al (2019) Interleukin-15 in cancer immunotherapy: IL-15 receptor complex versus soluble IL-15 in a cancer cell-delivered murine leukemia model. J Immunother Cancer 7(1):355","journal-title":"J Immunother Cancer"},{"key":"3442_CR7","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/696578","volume":"2015","author":"M Croce","year":"2015","unstructured":"Croce M, Rigo V, Ferrini S (2015) IL-21: a pleiotropic cytokine with potential applications in oncology. J Immunol Res 2015:696578","journal-title":"J Immunol Res"},{"issue":"6","key":"3442_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1399-0039.2009.01382.x","volume":"74","author":"H Sondergaard","year":"2009","unstructured":"Sondergaard H, Skak K (2009) IL-21: roles in immunopathology and cancer therapy. Tissue Antigens 74(6):467\u2013479","journal-title":"Tissue Antigens"},{"key":"3442_CR9","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3389\/fimmu.2018.00883","volume":"9","author":"A Sharma","year":"2018","unstructured":"Sharma A, Rudra D (2018) Emerging functions of regulatory T cells in tissue homeostasis. Front Immunol 9:883","journal-title":"Front Immunol"},{"issue":"1","key":"3442_CR10","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e4","volume":"20","author":"JH Kim","year":"2020","unstructured":"Kim JH, Kim BS, Lee SK (2020) Regulatory T cells in tumor microenvironment and approach for anticancer immunotherapy. Immune Netw 20(1):e4","journal-title":"Immune Netw"},{"issue":"10","key":"3442_CR11","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1158\/2159-8290.CD-16-0329","volume":"6","author":"MM Chen","year":"2016","unstructured":"Chen MM et al (2016) Polarization of tissue-resident TFH-like cells in human hepatoma bridges innate monocyte inflammation and M2b macrophage polarization. Cancer Discov 6(10):1182\u20131195","journal-title":"Cancer Discov"},{"issue":"3","key":"3442_CR12","first-page":"3917","volume":"16","author":"X Meng","year":"2018","unstructured":"Meng X et al (2018) Distribution of circulating follicular helper T cells and expression of interleukin-21 and chemokine C-X-C ligand 13 in gastric cancer. Oncol Lett 16(3):3917\u20133922","journal-title":"Oncol Lett"},{"issue":"2","key":"3442_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.canlet.2014.12.047","volume":"358","author":"MR Davis","year":"2015","unstructured":"Davis MR et al (2015) The role of IL-21 in immunity and cancer. Cancer Lett 358(2):107\u2013114","journal-title":"Cancer Lett"},{"issue":"2","key":"3442_CR14","doi-asserted-by":"publisher","first-page":"641","DOI":"10.4049\/jimmunol.121.2.641","volume":"121","author":"CJ Paige","year":"1978","unstructured":"Paige CJ, Kincade PW, Ralph P (1978) Murine B cell leukemia line with inducible surface immunoglobulin expression. J Immunol 121(2):641\u2013647","journal-title":"J Immunol"},{"issue":"6","key":"3442_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1163462","volume":"5","author":"T Jiang","year":"2016","unstructured":"Jiang T, Zhou C, Ren S (2016) Role of IL-2 in cancer immunotherapy. Oncoimmunology 5(6):e1163462","journal-title":"Oncoimmunology"},{"key":"3442_CR16","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3389\/fimmu.2013.00190","volume":"4","author":"DO Adeegbe","year":"2013","unstructured":"Adeegbe DO, Nishikawa H (2013) Natural and induced T regulatory cells in cancer. Front Immunol 4:190","journal-title":"Front Immunol"},{"issue":"1","key":"3442_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/08923973.2019.1566925","volume":"41","author":"S Najafi","year":"2019","unstructured":"Najafi S, Mirshafiey A (2019) The role of T helper 17 and regulatory T cells in tumor microenvironment. Immunopharmacol Immunotoxicol 41(1):16\u201324","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"2","key":"3442_CR18","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/mt.2008.249","volume":"17","author":"S Kim-Schulze","year":"2009","unstructured":"Kim-Schulze S et al (2009) Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment. Mol Ther 17(2):380\u2013388","journal-title":"Mol Ther"},{"issue":"5","key":"3442_CR19","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00262-017-1970-6","volume":"66","author":"V Kannappan","year":"2017","unstructured":"Kannappan V et al (2017) Interleukin 21 inhibits cancer-mediated FOXP3 induction in naive human CD4 T cells. Cancer Immunol Immunother 66(5):637\u2013645","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"3442_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4161\/mabs.2.1.10561","volume":"2","author":"A Gowda","year":"2010","unstructured":"Gowda A et al (2010) Differential effects of IL-2 and IL-21 on expansion of the CD4+ CD25+ Foxp3+ T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia. MAbs 2(1):35\u201341","journal-title":"MAbs"},{"issue":"20","key":"3442_CR21","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1182\/blood-2011-10-388546","volume":"119","author":"K Attridge","year":"2012","unstructured":"Attridge K et al (2012) IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis. Blood 119(20):4656\u20134664","journal-title":"Blood"},{"issue":"5","key":"3442_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003362","volume":"9","author":"I Schmitz","year":"2013","unstructured":"Schmitz I et al (2013) IL-21 restricts virus-driven Treg cell expansion in chronic LCMV infection. PLoS Pathog 9(5):e1003362","journal-title":"PLoS Pathog"},{"issue":"4","key":"3442_CR23","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.4049\/jimmunol.1302285","volume":"192","author":"A Vogelzang","year":"2014","unstructured":"Vogelzang A et al (2014) IL-21 contributes to fatal inflammatory disease in the absence of Foxp3+ T regulatory cells. J Immunol 192(4):1404\u20131414","journal-title":"J Immunol"},{"issue":"3","key":"3442_CR24","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaci.2011.05.029","volume":"128","author":"G Geri","year":"2011","unstructured":"Geri G et al (2011) Critical role of IL-21 in modulating TH17 and regulatory T cells in Behcet disease. J Allergy Clin Immunol 128(3):655\u2013664","journal-title":"J Allergy Clin Immunol"},{"key":"3442_CR25","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1146\/annurev.immunol.22.012703.104702","volume":"22","author":"F Sallusto","year":"2004","unstructured":"Sallusto F, Geginat J, Lanzavecchia A (2004) Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22:745\u2013763","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"3442_CR26","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1134\/S0006297913050143","volume":"78","author":"YY Silaeva","year":"2013","unstructured":"Silaeva YY et al (2013) Decrease in pool of T lymphocytes with surface phenotypes of effector and central memory cells under influence of TCR transgenic beta-chain expression. Biochemistry (Mosc) 78(5):549\u2013559","journal-title":"Biochemistry (Mosc)"},{"issue":"8","key":"3442_CR27","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1158\/2326-6066.CIR-15-0291","volume":"4","author":"RL Browning","year":"2016","unstructured":"Browning RL et al (2016) Lenalidomide induces interleukin-21 production by T cells and enhances IL21-mediated cytotoxicity in chronic lymphocytic leukemia B cells. Cancer Immunol Res 4(8):698\u2013707","journal-title":"Cancer Immunol Res"},{"issue":"13","key":"3442_CR28","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1182\/blood-2015-01-624585","volume":"126","author":"S Bhatt","year":"2015","unstructured":"Bhatt S et al (2015) Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma. Blood 126(13):1555\u20131564","journal-title":"Blood"},{"issue":"9","key":"3442_CR29","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s00262-007-0285-4","volume":"56","author":"H Sondergaard","year":"2007","unstructured":"Sondergaard H et al (2007) Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors. Cancer Immunol Immunother 56(9):1417\u20131428","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"3442_CR30","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1084\/jem.20152021","volume":"213","author":"AG Chapuis","year":"2016","unstructured":"Chapuis AG et al (2016) Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. J Exp Med 213(7):1133\u20131139","journal-title":"J Exp Med"},{"issue":"31","key":"3442_CR31","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1200\/JCO.2015.65.5142","volume":"34","author":"AG Chapuis","year":"2016","unstructured":"Chapuis AG et al (2016) T-cell therapy using interleukin-21-primed cytotoxic T-cell lymphocytes combined with cytotoxic T-cell lymphocyte antigen-4 blockade results in long-term cell persistence and durable tumor regression. J Clin Oncol 34(31):3787\u20133795","journal-title":"J Clin Oncol"},{"issue":"3","key":"3442_CR32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/sj.cgt.7700552","volume":"10","author":"S Ugai","year":"2003","unstructured":"Ugai S et al (2003) Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts. Cancer Gene Ther 10(3):187\u2013192","journal-title":"Cancer Gene Ther"},{"issue":"10","key":"3442_CR33","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/sj.cgt.7700630","volume":"10","author":"S Ugai","year":"2003","unstructured":"Ugai S et al (2003) Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects. Cancer Gene Ther 10(10):771\u2013778","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"3442_CR34","doi-asserted-by":"publisher","DOI":"10.4161\/2162402X.2014.994370","volume":"4","author":"ME Nelles","year":"2015","unstructured":"Nelles ME, Paige CJ (2015) CD4(+) T cell plasticity engenders robust immunity in response to cytokine therapy. Oncoimmunology 4(3):e994370","journal-title":"Oncoimmunology"},{"issue":"7","key":"3442_CR35","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","volume":"181","author":"DY Oh","year":"2020","unstructured":"Oh DY et al (2020) Intratumoral CD4(+) T cells mediate anti-tumor cytotoxicity in human bladder cancer. Cell 181(7):1612\u20131625","journal-title":"Cell"},{"issue":"7735","key":"3442_CR36","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-018-0694-x","volume":"564","author":"L Zhang","year":"2018","unstructured":"Zhang L et al (2018) Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature 564(7735):268\u2013272","journal-title":"Nature"},{"issue":"3","key":"3442_CR37","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1084\/jem.20091918","volume":"207","author":"SA Quezada","year":"2010","unstructured":"Quezada SA et al (2010) Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 207(3):637\u2013650","journal-title":"J Exp Med"},{"issue":"6","key":"3442_CR38","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.immuni.2019.10.009","volume":"51","author":"R Zander","year":"2019","unstructured":"Zander R et al (2019) CD4(+) T cell help is required for the formation of a cytolytic CD8(+) T cell subset that protects against chronic infection and cancer. Immunity 51(6):1028\u20131042","journal-title":"Immunity"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03442-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03442-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03442-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T03:21:29Z","timestamp":1689996089000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03442-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,15]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["3442"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03442-2","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,15]]},"assertion":[{"value":"6 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}